The FDA granted Medtronic Inc. (NYSE:MDT) approval for its Protecta series of implantable cardioverter-defibrillators, which had been delayed by regulatory snafus.
The Fridley, Minn.-based company’s resolution of a Nov. 2009 warning letter enabled the company to receive approval from the FDA for the Protecta ICD portfolio.
